Theratechnologies Income from Continuous Operations 2011-2024 | THTX

Theratechnologies income from continuous operations from 2011 to 2024. Income from continuous operations can be defined as a company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change

Theratechnologies Income from Continuous Operations 2011-2024 | THTX

Theratechnologies income from continuous operations from 2011 to 2024. Income from continuous operations can be defined as a company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$171.5B
Vertex Pharmaceuticals (VRTX)$121.6B
Gilead Sciences (GILD)$111.4B
Bristol Myers Squibb (BMY)$110.2B
Regeneron Pharmaceuticals (REGN)$93B
CSL (CSLLY)$90B
GSK (GSK)$76.4B
Argenex SE (ARGX)$35.6B
Alnylam Pharmaceuticals (ALNY)$35.3B
BioNTech SE (BNTX)$26.5B
Biogen (BIIB)$25.3B
Illumina (ILMN)$23.9B
Moderna (MRNA)$21B
BeiGene (BGNE)$19.9B
Genmab (GMAB)$14.9B
Incyte (INCY)$14.7B
Exact Sciences (EXAS)$12.9B
BioMarin Pharmaceutical (BMRN)$12.7B
Vaxcyte (PCVX)$12B
Bio-Techne Corp (TECH)$11.9B
Sarepta Therapeutics (SRPT)$11.8B
Insmed (INSM)$11.7B
QIAGEN (QGEN)$9.8B
Exelixis (EXEL)$9.7B
Bio-Rad Laboratories (BIO.B)$9.3B
Revolution Medicines (RVMD)$9.2B
Intra-Cellular Therapies (ITCI)$9.2B
Roivant Sciences (ROIV)$8.6B
Viking Therapeutics (VKTX)$8.1B
Legend Biotech (LEGN)$8.1B